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Mechanism of Sustained Release of Vascular
Endothelial Growth Factor in Accelerating
Experimental Diabetic Healing
Harold Brem1, Arber Kodra1, Michael S. Golinko1, Hyacinth Entero1, Olivera Stojadinovic2, Vincent M. Wang3,
Claudia M. Sheahan4, Alan D. Weinberg5, Savio L.C. Woo6, H. Paul Ehrlich7 and Marjana Tomic-Canic2
In this study, we hypothesize that local sustained release of vascular endothelial growth factor (VEGF), using
adenovirus vector (ADV)-mediated gene transfer, accelerates experimental wound healing. This hypothesis was
tested by determining the specific effects of VEGF165 application on multiple aspects of the wound healing
process, that is, time to complete wound closure and skin biomechanical properties. After showing accelerated
wound healing in vivo, we studied the mechanism to explain the findings on multiple aspects of the wound
healing cascade, including epithelialization, collagen deposition, and cell migration. Intradermal treatment of
wounds in non-obese diabetic and db/db mice with ADV/VEGF165 improves healing by enhancing tensile
stiffness and/or increasing epithelialization and collagen deposition, as well as by decreasing time to wound
closure. VEGF165, in vitro, stimulates the migration of cultured human keratinocytes and fibroblasts, thus
revealing a non-angiogenic effect of VEGF on wound closure. In conclusion, ADV/VEGF is effective in
accelerating wound closure by stimulating angiogenesis, epithelialization, and collagen deposition. In the
future, local administration and sustained, controlled release of VEGF165 may decrease amputations in patients
with diabetic foot ulcers and possibly accelerate closure of venous ulcers and pressure ulcers.
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INTRODUCTION
It is estimated that in excess of 4.5 million patients with
diseases of the skin and subcutaneous tissue visit emergency
departments across the country each year (Nawar et al.,
2007). Of these, diabetic foot ulcers (DFUs) pose the most
serious threat to patient safety. DFUs have multiple physio-
logical impairments to healing, including impaired innervation
(Gibran et al., 2002), impaired cellular migration
(Brem et al., 2007), and inadequate angiogenesis (Cho
et al., 2006), that lead to extensive mortality and limb
amputation in patients. Therefore, of all chronic wounds,
DFUs are the most insidious, as many patients do not realize
that they have a break in the skin, nor is the true extent of
infection always noticed by clinicians on presentation.
Foot ulcers have become one of the most common and
severe complications of diabetes and are now the leading
cause for hospitalization in patients with diabetes (Lavery
et al., 2007). The incidence of foot ulcers in the general
population ranges between 2 and 5% (Abbott et al., 2002;
Rathur and Boulton, 2007). Persons with type 1 and type 2
diabetes have a 9.1% risk of developing a foot ulcer in their
lifetime (Lavery et al., 2006), and the presence of an ulcer
may increase the risk of lower-extremity amputation by
almost six fold, affecting hospital stay and survival rate
(Valensi et al., 2005; Davis et al., 2006; Faglia et al., 2006;
Malay et al., 2006).
Angiogenesis is a vital component of wound repair
(Brem et al., 1997; Folkman, 2007) and there is a need for
a local, sustained therapy that can reverse this and other
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physiological impairments. Despite multiple advances (Mar-
ston et al., 2003; Veves et al., 2001; Steed, 1995; Steed,
2006) and a recombinant form of growth factor with
angiogenic effect—that is, PDGF, which has been approved
by the FDA for use in DFUs (Smiell, 1998; Smiell et al.,
1999)—a sustained release formulation has yet to be
approved. Vascular endothelial growth factor (VEGF) has
shown positive and safe results when administered alone or
as adjunctive therapy to angioplasty and surgery and in
ischemic heart disease (Stewart et al., 2006; Rosengart et al.,
1999a, b; Laitinen et al., 2000; Hedman et al., 2003).
However, studies that further elucidate the mechanism of
VEGF, which could better inform the design of clinical trial,
are needed.
VEGF is one of the most vital and potent angiogenesis-
stimulating growth factors, and it exists in many isoforms
derived from alternative splicing (Robinson and Stringer,
2001). The most common isoform is VEGF165. The functions
of VEGF are multifold. It acts in a paracrine manner on both
endothelial cells and dermal microvessels. Furthermore, it
functions as an endothelial cell mitogen, a chemotactic
agent, and an inducer of both vascular and skin permeability
(Ferrara, 1999; Yamagishi et al., 1999; Griffoen and Molema,
2000; Brkovic and Sirois, 2007; Gavard and Gutkind, 2006).
One of the mediators of VEGF activity, nitric oxide, enhances
collagen deposition in diabetic wounds and may restore
endothelial function to improve both nerve conduction and
tissue oxygenation (Witte et al., 2002). Recombinant VEGF
has been applied in experimental diabetic wounds in vivo
and in vitro (Table 1) (Iwaguro et al., 2002; Romano Di Peppe
et al., 2002; Shimpo et al., 2002; Vajanto et al., 2002; Chang
et al., 2003; Michaels et al., 2005; Huang et al., 2006;
Saaristo et al., 2006; Li et al., 2007). However, recombinant
VEGF requires frequent repeated topical applications for
Table 1. A compilation of recent studies on therapeutic angiogenesis involving release of VEGF165 in animal models
Authors Delivery system/(species) Assay Endpoints
Huang et al. ADV-21010 vp (rat) Time to viable skin area Increased skin flap viability. Increase in NO
synthesis
Iwaguro et al. ADV/VEGF (1.5104) vp (mice) Laser Doppler perfusion imaging (LDPI):
used to record blood flow measurements.
ELISA: used to quantify VEGF levels in
plasma
Histology: to evaluate vascular density
Neovascularization and blood flow recovery
improved. Limb necrosis/auto-amputation
Reduced by 63.7% in comparison with
control animals.
Makinen et al. ADV/VEGF (21010) vp (human) Digital subtraction angiography: to evaluate
vascularity
ABI analysis
Increased vascularity in the VEGF-treated
group. Improvement in ABI.
Chang et al. Adeno-associated viral vectors
(51011) vp (rat)
Immunohistochemistry: to determine
cellular proliferation and capillary-to-muscle
ratios
RTPCR: to detect hVEGH levels in muscles
Skeletal muscle oxygen tension normalized.
Arteriogenesis induced. No significant
increase in angiogenesis in rats with severe
hind-limb ischemia.
Vajanto et al. ADV-mouse VEGF—21010 vp
(rabbit)
Angiography: for vascularization
Histology: to asses granulation levels
-ELISA: to detect VEGF concentration
Induction of angiogenesis. Hind limb and
testes edema were observed.
Shimpo et al. Adeno-associated virus with
hVEGF—2 1013 vp (rat)
ELISA: to detect VEGF concentration
–RT-PCR: to assess gene expression
-Ultrasound Flowmeter: to detect Blood flow
in arteries
Histology: to analyze capillary density.
Efficient and stable gene expression without
ectopic expression. Stimulation of
angiogenesis and improved blood flow.
Romano Di Peppe
et al.
ADV/VEGF (1108) vp (mice) Histology: check increase in granulation
Time to closure measurement
Reduction of time to closure of wound, and
increase in granulation tissue density.
Saaristo A. et al. ADV/VEGF (1108) vp (mice) Histology: density of blood vessels
Time to full wound closure
Promotion of angiogenesis through increase
in blood vessel density and reduction of time
to closure of wound.
Li Y. et al. ZFP-VEGF—125 mg (mice) mRNA and protein quatification
Histology: capillary density
Induction of angiogenesis as observed and
increase in capillary density. Increase in
quantity of VEGF mRNA, protein
Kirchen LM. et al. PEG-VEGF (1mg) (mice) Histology: chronic inflammation and
neovascularization
Time to full wound closure
Promotion of angiogenesis by an increase in
neovascularization and a decrease in time to
full closure of wound
Michaels J 5th.
et al.
Topical treatment of VEGF 10 mg
(mice)
Histology:neovascularization
Time to complete wound closure
Increase in neovascularization by VEGF
treatment. Decrease in time to full closure
ABI, ankle brachinl index; ADV, adenovirus vector; NO, nitric oxide; PEG, polyethylene glycol; VEGF, vascular endothelial growth factor, ZFP, Zinc Finger
DNA protein.
Recombinant VEGF has been shown to stimulate angiogenesis, but has also caused serious side effects such as edema.
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sustained drug levels in the local tissue, which may be a
reason it has not been successful in clinical trials for DFUs.
Because sustained release of VEGF has shown promise, but
has not yet benefited patients with chronic wounds, we
suggest that the mechanism of VEGF in wound healing may
not be fully understood.
Gene therapy with VEGF is an attractive alternative as it
can provide local, sustained release without systemic
toxicity. Gene therapy has already proven effective in a
variety of experimental wound healing models (Eming et al.,
1999; Chandler et al., 2000; Crombleholme, 2000; Davidson
et al., 2000; Yao and Eriksson, 2000; Keswani et al., 2004;
Lee et al., 2005b; Saaristo et al., 2006). For gene therapy to
be effective in chronic wounds, the gene must be efficiently
delivered to the specific target cell in which it must be
expressed and sustained locally without significant systemic
absorption (Levy et al., 2001; Aoyama et al., 2003). Vector-
mediated gene therapy meets these criteria (Galeano et al.,
2003). VEGF alone or in combination with other treatment
modalities may prove to be an effective treatment for diabetic
vascular disease and ulcers. This possibility is confirmed by
the demonstration that gene therapy with VEGF restores the
impaired angiogenesis found in ischemic limbs of diabetic
mice (Rivard et al., 1999). In this study we show that both
in vivo, in experimental diabetic wound models, and in vitro,
in primary cultured cells from patients with DFUs, a local
sustained delivery of VEGF using adenovirus vector (ADV)
promotes epithelialization and wound closure, enhances
granulation tissue formation, increases tensile stiffness,
promotes wound contraction, and increases collagen deposi-
tion. We conclude that ADV/VEGF accelerates wound
healing in a diabetic wound model, underscoring its potential
use as topical gene therapy in patients with DFUs.
RESULTS
ADV/VEGF165 accelerates time to closure in db/db mice
To determine whether ADV/VEGF165 accelerates wound
healing, time to wound closure was determined using four
different doses of ADV/VEGF165. Wounds treated with ADV/
VEGF165 healed 6.6 days sooner than controls (Figure 1).
Treated wounds healed in 27.2±1.4 days. Saline-treated
wounds healed in 34.2±7.0 days, whereas wounds that were
treated with the virus vector alone healed in 33.5±6.5 days.
Statistical significance (Po0.05) was noted after comparison
of the 5 1011 vp per wound VEGF165-treated group and
control groups (Table 2). However, such high doses of
VEGF165 may have a toxic effect in the mice used in the
study, as the incidence of mortality in the high-dosage
VEGF165-treated group was greater than in other groups. A
minimum 10% increase in mortality relative to controls was
found at ADV/VEGF doses of 5109 vp per wound and higher.
ADV/VEGF165 promotes epithelialization
To determine the effects of ADV/VEGF on re-epithelializa-
tion, we performed histological analysis and found increased
re-epithelialization in 5 108 ADV/VEGF-treated wounds
versus controls (Po0.05) in day 10 db/db diabetic mice
(Table 3). Increased re-epithelialization was qualitatively
observed in samples from day 14 non-obese diabetic (NOD)
mice treated with VEGF compared with the controls (data not
shown). The width of the fourteenth day ADV/VEGF-treated
open wounds was less than the width of the saline- and
empty virus-treated wounds. In the ADV/VEGF165-treated
open wounds, wound contraction was enhanced, in that the
surrounding skin was pulled into the wound, decreasing the
area of open wound and increasing the area of normal skin
covering the initial wound. Consistent with more rapid re-
epithelialization, the volume of granulation tissue was
reduced in the ADV/VEGF-treated wounds compared with
the two other treated wound groups. Therefore, we conclude
that in open wounds VEGF treatment enhanced re-epithelia-
lization.
Mechanism of VEGF and epithelialization
Our observation that ADV/VEGF accelerated time to closure
and promoted epithelialization in mice prompted us to
explore this finding in vitro. To establish whether VEGF
stimulates keratinocyte migration, normal primary human
epidermal keratinocytes were used in an in vitro scratch-
wound assay. When normal human keratinocytes grown in
Control
Day 0
Day 10
Day 16
VEGF
Figure 1. ADV/VEGF165 accelerates time to closure in db/db mice.
Photograph of the time to closure experiment showing accelerated time to
closure in db/db mouse wounds treated with ADV/VEGF compared with wild-
type control.
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tissue culture are ‘‘wounded,’’ they migrate over the scratch
area to close the gap. Data from experiments suggested that
VEGF165 accelerated cell migration after 24 hours and further
after 48 hours (Figure 2a). As expected, cells incubated with
epidermal growth factor, which was used as a positive
control because it is a potent stimulator of keratinocyte
migration and proliferation, migrated significantly faster than
untreated, control cells (Figure 2a). To distinguish whether
VEGF affects migration directly or indirectly, by promoting
proliferation, an analogous experiment with Mitomycin C
treated keratinocytes was performed and produced similar
results. VEGF165 stimulated migration of Mitomycin C treated
keratinocytes, thus confirming that VEGF has direct effects on
keratinocyte migration (results not shown). Taken together,
our results suggest that VEGF promotes epithelialization via
migration of keratinocytes.
To test which keratinocyte phenotype is susceptible to
VEGF stimulation, the effects of VEGF165 were tested on
wound healing and differentiating cell phenotypes. Keratino-
cytes grown in culture medium containing low calcium
(0.09mM) resemble the activated keratinocyte phenotype,
the cells that actively participate in re-epithelialization.
Table 2. Effect of different concentrations of VEGF165 on time to wound closure in BKS.Cg-m+/+Lepr
db type 2
diabetic male mice
Time to closure in db/db male mice
Treatment Dosage (vp per wound)
Mean time to closure±SD
(days)
ADV/VEGF165 5.0 1011 25.4±3.9
1.6 1011 27±4.3
5.0 1010 28±5.8
1.6 1010 28.6±3.2
Saline Saline 34.2±7.0
DL-312 (5 108 vp) (vehicle
control)
5 1011 33.5±6.5
P-values ADV/VEGF165 (5.0 1011) ADV/VEGF165 (1.6 1011) ADV/VEGF165 (5.0 1010) ADV/VEGF165 (1.6 1010)
Saline 0.028 0.070 0.145 0.173
DL-312 (5 108 vp) 0.029 0.08 0.125 0.147
ADV, adenovirus vector; VEGF, vascular endothelial growth factor.
Data indicate that administration of VEGF165 leads to a decrease in the time it takes for wounds to close. On average wounds treated with VEGF165 healed
6.6 days faster than the wounds that did not get treated with it.
Table 3. Histological grading and scores of day 10 wounds at incision site of female BKS.Cg-m+/+Leprdb type 2
diabetic mice
H&E
Treatment n Epithelialization (0–4)±SD # of cells/HPF±SD
Treated (ADV/hVEGF 5 108 vp per wound) 8 3.6±0.8 453±156
DL-312 5 108 vp per wound 7 2.1±1.1 283±104
Saline 8 2.6±0.7 335±57
Comparison P-values
ADV/VEGF vs saline
H&E: Epith (0–4) 0.017
ADV/VEGF vs vehicle
H&E: Epith (0–4) 0.008
Saline vs vehicle
H&E: Epith (0–4) 0.170
ADV, adenovirus vector; H&E, hematoxylin and eosin; VEGF, vascular endothelial growth factor.
Statistically significant increase in epithelialization was observed after H&E staining of ADV/VEGF165 and control groups.
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However, keratinocytes grown in a high calcium (1.2mM)
medium resemble differentiating keratinocytes (Bikle et al.,
2004). As their proliferation rate decreases, they form
desmosomal junctions and start stratifying in culture,
contributing minimally to re-epithelialization. Interestingly,
VEGF165 did not stimulate migration of differentiated
keratinocytes in scratch-wound assays (Figure 2b). This
suggests that VEGF165 specifically targets only keratinocytes
that participate in re-epithelialization, and differentiating
keratinocytes are not affected.
ADV/VEGF increases tensile stiffness in db/db mice at day 21
To determine how VEGF affects the quality of healing,
mechanical properties such as load to failure and stiffness
were measured for incisional wounds on female BKS.
Cg-mþ /þ Leprdb mice. Measurements were taken 10 and
0 hours
Control
VEGF
EGF
0 hours 24 hours 48 hours
Control
VEGF
EGF
24 hours 48 hours
Figure 2. VEGF promotes migration of activated, but not differentiating keratinocytes. (a) Activated keratinocyte migration with the addition of VEGF and EGF
(epidermal growth factor) at different time points after scrape wounding of the keratinocyte monolayer. Keratinocytes residing in low calcium are activated
keratinocytes. VEGF165 and EGF stimulated migration of activated keratinocytes over the wound area. These keratinocytes most closely resemble keratinocytes
that are responsible for wound re-epithelialization. (b) Differentiated keratinocyte migration at different time points after release of VEGF165 into the wound area.
When maintained in high concentrations of calcium, keratinocytes become differentiated. These differentiated keratinocytes least resemble those keratinocytes
that participate in wound re-epithelialization. Results show that VEGF165 does not have a significant effect on their migration, but EGF continues to promote their
migration in a scratch-wound assay. Bar¼0.05mm.
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21 days after wounding of treatment groups, which received
5108 or 5 1010 vp per wound, and saline and vehicle
controls. On postoperative day 10, the loads to failure
(mean±SD) were 0.83±0.4 and 0.78±0.2N for groups I
and III. Groups II and IV had maximum loads at 1.06±0.4
and 0.54±0.3N, respectively (Table 4). Stiffness (mean±SD)
values were 0.50±0.2, 0.59±0.2, 0.42±0.1, and
0.32±0.2N/mm for groups I, II, III, and IV, respectively
(Table 4). No significant mechanical changes had appeared
by 10 days, comparing the ADV/VEGF-treated groups and the
control groups. On postoperative day 21 in the BKS.Cg-mþ /
þ Leprdb full-thickness incisional wounds, the loads to failure
(mean±SD) were 4.27±0.70, 4.46±0.90, 3.57±0.60, and
3.72±0.60N (Table 4). No statistically significant changes
were obtained between the groups. Stiffness values
(mean±SD) were 1.70±0.20, 1.53±0.40, 1.17±0.15, and
1.13±0.20N/mm for ADV/VEGF165 5 108 vp per wound,
ADV/VEGF165 51010 vp per wound, vehicle, and saline
groups (Table 4). A statistically significant (Po0.05) change
was observed between the ADV/VEGF165 5 1010 vp per
wound and the vehicle control group. There was no
statistically significant difference in tensile stiffness at day
21 in the NOD mice (Table 5).
ADV/VEGF165 promotes wound contraction through collagen
deposition
Differences in the cellular density of ADV/VEGF165-treated
wounds compared with saline and empty virus-treated
wounds were clearly shown histologically (Figure 3).
Saline-treated, control full excisions showed complete
re-epithelialization and contained typical granulation tissue
with a moderate cell density and prominent blood vessels
Table 4. Effect of different concentrations of VEGF165 on tensile strength and stiffness in db/db mice
Group (Vol: 200ll) Testing day Age (wks)
Pre-wounding
BW (g)±SD
Pre-testing
BW (g)±SD Mice (n)
Stiffness
(N/mm)±SD
Max load
(n)
I ADV/VEGF165 (5 1010 vp) 10 9 30±1.7 30.1±2.8 6 0.50±0.2 0.83±0.4
II ADV/VEGF165 (5 108 vp) 10 9 30.8±2.2 31.5±3.1 6 0.59±0.2 1.06±0.4
III Saline (control) 10 9 30.6±4.1 34.1±4.7 6 0.42±0.1 0.78±0.2
IV DL-312 (5 108vp) (vehicle
control)
10 9 31.5±3 33.2±3.5 6 0.32±0.2 0.54±0.3
I ADV/VEGF165 (5 1010vp) 21 11 30±1.8 32.9±2.5 6 1.70±0.2 4.27±0.7
II ADV/VEGF165 (5 108vp) 21 11 32±3.0 34.1±4.3 6 1.53±0.4 4.46±0.9
III Saline (control) 21 11 31.2±1.9 34.2±4.3 6 1.17±0.15 3.57±0.6
IV DL-312 (5 108vp) (vehicle
control)
21 11 31.1±2.3 33.2±1.6 6 1.13±0.2 3.72±0.6
ADV, adenovirus vector; VEGF, vascular endothelial growth factor.
Results indicate that release of VEGF165 at the wound area leads to an increase in the tensile stiffness as compared with controls.
Bold text indicates day at which significant difference in tensile stiffness was observed.
Table 5. Effect of different concentrations of VEGF165 on skin stiffness in NOD mice
Group (Vol: 200ll)
Test
day
Age
(wks)
HbA1c
(%)±SD
Pre-
wounding
BW (g)±SD
AM glucose
(mg per 100
ml)±SD
Glucose
(2 hours-post
insulin)
DAY 0±SD
Glucose
(5 hours-
post insulin)
DAY 7±SD
Pre-testing
BW (g)±SD
AM Glucose
(mg per
100 ml)±SD
A ADV/VEGF165 (5 108 vp) 14 30 7.8±2.1 26.6±1.1 553±110 179±126 237±149 27.6±1.8 519±164
B Saline (control) 14 30 7.5±2.2 26.4±1.5 469±168 209±114 125±101 27.5±2.7 498±157
C DL-312 (5108vp) (vehicle
control)
14 30 7.6±2.1 26.4±1.3 502±170 228±121 164±142 27.9±1.5 526±157
Mice
(N)
Mortality
(n)
Stiffness
(N/mm)±SD
Load to failure
(N)±SD
A ADV/VEGF165 (5 108 vp) 10 0 1.47±0.4 3.03±0.8
B Saline (control) 10 0 1.50±0.3 3.26±1.0
C DL-312 (5108vp) (vehicle
control)
10 0 1.49±0.3 3.62±0.8
ADV, adenovirus vector; NOD, non-obese diabetic; VEGF, vascular endothelial growth factor.
Results indicate that delivery of VEGF165 at the wound site in mice does not lead to a significant increase in tensile strength and stiffness as compared with
controls.
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(Figure 3a). No neutrophils were identified and few macro-
phages were present. Most of the cell populations in these
saline-treated wounds were mesenchymal cells (fibroblasts
and myofibroblasts). The empty virus particle-treated mouse
wounds, like the saline controls, were completely re-
epithelialized. The granulation tissue was similar to the
saline controls (Figure 3b). The integration of granulation
tissue with the subdermal adipose tissue was similar to that of
the saline controls, and most cells within the granulation
tissue were mesenchymal cells. The ADV/VEGF165-treated
wounds were completely re-epithelialized and the granula-
tion tissue showed thicker pink staining in the deeper regions
of the granulation tissue. The number and luminal size of the
blood vessels in the ADV/VEGF165-treated wounds were
greater than in the other treatment groups (Figure 3c). In
addition the cell density was greater throughout in the
epidermal layer compared with the saline and empty viral
particle controls. By histological evaluation, ADV/VEGF165-
treated wounds showed enhanced granulation tissue deposi-
tion, containing greater numbers of larger vessels, compared
with the non-VEGF-treated wounds. In addition, the epider-
mal layer covering the VEGF-treated wounds was thicker and
had a greater basal cell density (Figure 3c), which is
consistent with the in vitro findings of VEGF165 effects on
human keratinocytes (see Figure 1).
To evaluate the granulation tissue collagen fiber orienta-
tion and density in the matrix deposited in the three treatment
groups, Sirius red staining viewed with polarized light
microscopy was employed (Figure 4). Saline-treated control
wounds showed modest birefringence intensity, which
was consistent with new immature collagen fiber bundles
(Figure 4a). These collagen fiber bundles were short, thin, and
arranged in a random pattern. This birefringence pattern
would be typical of young immature granulation tissue. The
red birefringence on the surface of the granulation tissue is
from the keratin laid down by keratinocytes from the
epidermal layer. In these saline-treated mice, there is a
modest amount of collagen deposited and the newly
deposited collagen is poorly organized. Empty viral parti-
cle-treated wounds showed an increase in the birefringence
intensity, in which the fragments of collagen fiber bundles
were longer in size and arranged in a parallel manner
compared with saline-treated controls (Figure 4b). The
increase in collagen deposition and organization may have
resulted from viral particles causing a more intense acute
inflammatory response early in the repair process. This
response would have occurred soon after viral treatment
and may have promoted a modest increase in connective
tissue deposition. The ADV/VEGF165-treated wounds stained
with hematoxylin and eosin (H&E) (Figure 3c) showed thicker
granulation tissue, and when viewed by polarized light the
Sirius red-stained sections (Figure 4c) showed greater
amounts of collagen laid down in a more organized manner
(Figure 4c). The intense, thick continuous bands of birefrin-
gence were in contrast to the fragmented birefringence patterns
of the saline- and empty viral particle-treated wounds.
The intense birefringence of the ADV/VEGF165-treated wounds
was consistent with the more intense pinkish staining
shown by H&E (Figure 3c), and both histological methods
showed greater amounts of collagen deposition, laid
GT
AT
GT
AT
AT
GT
Figure 3. ADV/VEGF165 enhances granulation tissue deposition. Typical
H&E-stained histological sections from non-obese diabetic (NOD) mice
showing healing open wounds at 14 days. Panel (a) originates from a saline-
treated wound with an intact epidermal cell layer covering the granulation
tissue (GT), which is associated with the underlying adipose tissue (AT) layer.
Panel (b) originates from an empty virus particle-treated wound that was
covered by an intact epidermal cell layer above GT that covers the adipose
tissue. Panel (c) originates from an ADV/VEGF165-treated wound, in which
the epidermal layer and GT layer are thicker in depth and the granulation
tissue contains greater cell density with numerous large blood vessels. Arrows
indicate granulation tissue deposition. Bar¼ 0.08mm.
Figure 4. ADV/VEGF165 enhances collagen organization. Sirius red-stained
histological sections from healing open wounds in non-obese diabetic (NOD) mice
were viewed with polarized light. Panel (a) is from a control, saline-treated full
excision wound showing fragmented spots of birefringence with little intensity, due
to minimal organization of collagen fiber bundles. The intense red birefringence on
the upper surface of the section is from the keratin associated with a new epidermal
surface layer. Panel (b) is from an empty viral particle-treated full excision wound
that shows a more continuous birefringence pattern of greater intensity compared
with the control. This birefringence pattern is a consequence of longer collagen
fiber bundles that are arranged in parallel arrays. Panel (c) is from an ADV/
VEGF165-treated full excision wound with very long collagen fiber bundles
showing an intense red, continuous birefringence pattern, which is consistent with
more uniform packing of newly deposited collagen fiber bundles. Bar¼ 0.08mm.
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down in a more organized manner compared with the
controls.
Mechanism of VEGF and collagen deposition
To further elucidate the mechanism underlying these in vitro
findings in migrating fibroblasts in culture, we specifically
tested VEGF using in vitro scratch-wound assays with human
fibroblasts. Cells derived from distinct human wound loca-
tions were incubated in the presence and absence of human
recombinant VEGF. Their response to wound healing stimuli
was location specific. VEGF was most effective in stimulating
migration of fibroblasts deriving from Location C, the healing
edge, followed by those from Location A, the base of the
wound. Fibroblasts from the non-healing edge (Location B)
were not responsive (Figure 5a–d). These results were
quantified and the percentage of wound area coverage is
shown graphically in Figure 5e.
DISCUSSION
Results show that VEGF165 significantly enhances healing as
defined by an increase in re-epithelialization, production of a
more vascularized granulation tissue, and more organized
collagen fiber bundles. These effects are consistent with an
increase in tensile stiffness. Furthermore, experiments on the
effect of VEGF165 on time to complete wound closure suggest
that VEGF165 accelerates wound re-epithelialization rather
than promoting wound contraction, as defined by more rapid
reduction in open wound area over time.
The increase in re-epithelialization by VEGF165-treated
wounds has been reported by others (Romano Di Peppe
et al., 2002; Michaels et al., 2005; Saaristo et al., 2006;
Li et al., 2007). Data from this study confirm by histology the
improvement in re-epithelialization. The rationale for the
in vitro portion of this study was that restoration of an intact
epidermal barrier through wound re-epithelialization is the
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Figure 5. VEGF promotes migration of fibroblasts isolated from a specific wound location in patients. Human recombinant VEGF accelerates
migration of fibroblasts deriving from Location C. (Full lines indicate initial wound area; dotted lines demarcate the migrating front of cells.) VEGF stimulates
migration of fibroblasts deriving from Location C in a scratch-wound assay compared with untreated cells (c). VEGF treatment of fibroblasts deriving from
Location A (a) and Location B (b) did not stimulate migration significantly. Fibroblasts derived from these wound locations migrate at a rate similar to that of
untreated cells. (d) Uncovered surface areas from scratch wounds are shown. VEGF markedly reduced the wound area of fibroblasts from Location C. (e)
Quantification of fibroblast cell migration from the scratch assay. Epidermal growth factor was used as a positive control. The bar graph presents the percentage
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essential feature of wound closure. The directed migration of
keratinocytes is critical to wound re-epithelialization and
defects in this function are associated with the clinical
problem of chronic non-healing wounds (Raja et al., 2007).
The possible mechanism of enhanced wound closure is
substantiated in vitro by the specific effect of VEGF165 on
enhanced keratinocyte migration. Moreover, VEGF165 stimu-
lated the migration of activated keratinocytes over the wound
area. The activated keratinocyte is the phenotype that
participates in wound closure and that is permissive to
therapeutic modalities, including ADV/VEGF165. This indi-
cates that VEGF165 therapy promotes epithelialization,
independent of its role in recruiting and stimulating
endothelial cells in the repair process. Re-epithelialization
is a crucial component of wound closure. Retarded re-
epithelialization is one of the main causes of delayed wound
closure in diabetic patients.
The more rapid maturation of granulation tissue in the
VEGF165-treated wounds was shown by more and better
organized collagen fiber bundles deposited in granulation
tissue, which was confirmed histologically by H&E and Sirius
red staining. Collagen is the major connective-tissue compo-
nent of granulation tissue, scar, and dermis. Collagen
synthesis and deposition are critical for wound closure and
the development of wound tensile stiffness. The collagen
fiber bundles in granulation tissue become more organized as
the connective tissue in wounds matures and increases in
tensile stiffness. The greater cell density in the granulation
tissue of VEGF165-treated wounds, also observed through
histology, is believed to be due to an increase in the number
of fibroblasts at the wound site by enhanced cell migration.
In vitro VEGF165 has been shown to stimulate the
migration of primary fibroblasts deriving from patients with
chronic ulcers (Stojadinovic et al., 2007). VEGF165 specifi-
cally targets fibroblasts in the post-debrided wound, whereas
it has no effects on the migration of fibroblasts within the non-
healing edge. Further study is necessary to elucidate the
correlation of fibroblast migration and collagen synthesis and
deposition.
A recognized limitation of this analysis is the exclusive
focus on VEGF. VEGF alone may not be responsible for the
observed effects, as it is well known that VEGF upregulates
the expression of various cytokines and PDGF. Moreover, the
receptors for VEGF in different locations of the wound may
vary in expression, as might those for other growth factors.
Although we have shown decreased VEGFR at the non-
healing edge using microarrays (Stojadinovic et al.,
2008), expression levels at multiple locations in the wound
are a subject of future research. Identification of the role of
other growth stimulators and their receptors may also be
beneficial.
A sporadic finding was the mortality of some of the mice
that were given higher doses of ADV/VEGF (up to 51011)
relative to controls. No outward signs of abnormalities were
observed in the mice that died. We are not aware of a direct
link between VEGF administration and mortality. The safety
record of administration of adenovirus gene therapy is quite
good. A large study of low dose (o5e9) and intermediate
dose of viral particles (109 to 1011) in 90 individuals using six
different routes of administration drew results from multiple
clinical trials. The longitudinal study reported no mortalities
related to the administration of gene therapy and a major
adverse event rate of 0.7% (Harvey et al., 2002).
On the basis of the safety record of ADV and VEGF in
animal studies and human clinical trials, we can say with
reasonable certainty that the observed mortality was an
anomaly, probably due to the fragility of the mice and/or
intolerance of anesthesia, but which was unlikely to have
stemmed from the administration of ADV/VEGF. It is
necessary that further studies be performed regarding the
optimal effective dose of ADV/VEGF165 (in viral particles) in
type 1 and type 2 diabetic models to increase the efficacy of
the treatment while avoiding toxicity.
Taken together, these results show that VEGF increases
granulation tissue and promotes keratinocyte migration, and
both are expected to stimulate wound closure in diabetic
wound models in vivo. Knowledge about the effects of
VEGF165 on epithelialization, collagen deposition, and cell
migration may bring to fruition more gene therapy studies
involving the administration of VEGF165 as a treatment. Such
trials would be exceptionally important, particularly to target
patients with DFUs to decrease amputations. In addition,
ischemic ulcers could be targeted with ADV/VEGF.
MATERIALS AND METHODS
Construction of an ADV expressing bioactive human VEGF for
murine study
Human umbilical vein endothelial cells (HUVECs) were homo-
genized and total RNA was extracted. The full-length human
VEGF165 cDNA was amplified by PCR with appropriate primers
containing restriction sites (HindIII and XbaI) for subcloning into
pBluescript (Stratagene, La Jolla, CA). After sequence confirmation,
the human VEGF-165 cassette was cloned into the multiple cloning
site of an adenovirus shuttle vector (pXC1) containing adenovirus
type 5 sequences (bp 22–5,790) and a Rous sarcoma virus promoter.
This same vector was used as the positive control Dl-312 in the
experiments. For the rescue of the recombinant adenovirus, we
successfully used the two-plasmid co-transfection system (Microbix
Biosystems, Inc., Toronto, Ontario, Canada). Virus particle titer was
determined by optical absorbance at 260 nm, and plaque-forming
unit titer (pfuml1) was quantified by standard agarose overlay
plaque assay on 293 cells. Plaque-forming unit (pfu) determination
can vary up to one order of magnitude when the same batch of virus
is used in different assays, causing a significant variation in particle
measurement. To prevent this problem and to keep the viral loads
constant, the same batch of virus was used for all in vitro and in vivo
experiments.
JC cells, a VEGF-negative murine breast cancer cell line that
is easily transducible by adenoviruses, were infected with a
multiplicity of infection of 100 pfu per cell of several different viral
plaques (plaques 11-1, 11-2, 11-3, 11-9, 13-1, 16-1) of ADV/
VEGF165 or ADV/b Gal (negative control). VEGF165 was measured
after 48 hours in the conditioned supernatant of these virally
infected cells by hVEGF ELISA (R&D Systems, Minneapolis, MN).
Plaques 11-1, 13-1, and 16-1 were then selected to test for the
functional activity of the secreted VEGF165 in an in vitro bioassay
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(HUVEC proliferation assay), in which HUVEC proliferation
was induced by serial dilutions of conditioned supernatant of
ADV/VEGF165- or ADV/b Gal-transduced JC cells. HUVECs
were seeded in flat-bottom 96-well plates that were precoated
with 1% gelatin (in PBS) at 2 103 cells per well and serum
deprived overnight (M13 medium without FBS). Conditioned
supernatant was then added in several dilutions and cells were
cultured for an additional 48 hours in M13 supplemented with
20% FBS. HUVEC proliferation was measured by a tetrazolium-
based assay at an absorption of 450 nm, according to the
manufacturer’s instructions (Roche, Pleasanton, CA). Plaque 11-1
was selected for the large-scale amplification and virus purification
used in our experiments.
BKS.Cg-mþ /þ Leprdb and NOD mice
All animal procedures were performed with approval from the
Institutional Animal Care and Use Committee. All the mice were
acclimatized in individual cages for at least 2 weeks before
wounding. Glucose and body weight measurements were taken
before acclimation, wounding, and mechanical testing.
Wounding and testing were initiated at the ages of 24 and 27
weeks in female NOD mice because the type 1 diabetes peak
incidence in female NOD mice is attained at 16–20 weeks. Weekly
glucose monitoring was initiated by measuring plasma glucose levels
at 12 weeks of age and then bi-weekly, starting at 16 weeks of age,
as insulin-dependent diabetes mellitus is usually indicated when
plasma glucose levels reachX200mg per100 ml for two consecutive
weeks. A mixture of intermediate-acting and long-acting insulin
(Novolin 70/30, Novo Nordisk Pharmaceuticals, Inc., Princeton, NJ)
was injected subcutaneously daily to control blood glucose. Before
the experiment was begun, a portable monitor was used to measure
hemoglobin A1c (DCA2000þAnalyzer, Bayer, Terrytown, NY). A
glucometer (Ascencia Elite, Bayer, Terrytown, NY) was also used to
ensure that the groups had comparable glucose control.
Male and female BKS.Cg-mþ /þ Leprdb type 2 diabetic mice
(8 weeks old) were obtained from The Jackson Laboratory (Bar
Harbor, ME). They were housed in a temperature-controlled facility
with a 12-hour light/dark cycle. Water and standard rodent diet were
given ad libitum. When the animals were fasted for 12 hours, only
water was supplied.
Time to 100% closure using excisional wounds on diabetic mice
In preparation for all experiments, mice were anesthetized by
intraperitoneal injection of a ketamine and xylazine mixture. Mice
were shaved the day before experimentation. Full-thickness exci-
sional wounds, 1.4 cm in diameter, were created on the dorsum of
53 male BKS.Cg-mþ /þ Leprdb type 2 diabetic 8-week-old mice.
The mice were divided into six groups: group I (n¼ 12), ADV/
VEGF165 5 1011 vp per wound; group II (n¼ 8), ADV/VEGF165
1.6 1011 vp per wound; group III (n¼ 8), ADV/VEGF165 5 1010
vp per wound; group IV (n¼ 8), ADV/VEGF165 1.6 1010 vp per
wound; group V (n¼ 7), saline (negative control); group VI (n¼ 10),
DL-312 (positive control) 5 1011 vp per wound. Each injection of
ADV/VEGF165 or controls was administered intradermally around
the wound edge at the time of wounding. The marked areas were
excised with scissors to include the epidermis, dermis, and
panniculus carnosus. The wounds were digitally photographed at a
fixed distance on the day of wounding and then every fourth day
until the day of closure. A ruler was placed in the field of the
photograph, labeled with the mouse’s identification number and the
date. Time to closure was clinically evaluated and defined as the day
of 100% epithelialization with no drainage.
Tensile strength analysis using full-thickness incisional wounds
on diabetic mice
Linear incisional wounds were created on the dorsum of 57 female
BKS.Cg-mþ /þ Leprdb type 2 diabetic mice and in 42 female NOD
type 1 diabetic mice. Before being wounded, the animals were
acclimatized for 2 weeks by being placed in individual cages. They
were prepared for surgery as described earlier. A 30-mm linear
incision was initiated 5mm below the last cervical vertebra on the
dorsum of each animal in a longitudinal direction. Intradermal
injections of ADV/VEGF165 were administered at both sides of the
incision at the third suture location only. The BKS.Cg-mþ /þ Leprdb
mice were divided into four treatment groups: group I (n¼ 12), ADV/
VEGF165 5 1010 vp per wound; group II (n¼ 15) ADV/VEGF165
5 108 vp per wound; group III (n¼ 15), DL-312 vehicle (positive
control) 5 108 vp per wound; and group IV (n¼ 15), saline
(negative control). Similarly, NOD mice were divided into three
treatment groups: group I (n¼ 14) ADV/VEGF165 5 108 vp per
wound; group II (n¼ 14) DL-312 vehicle (positive control) 5 108
vp per wound; group III (n¼ 14) saline (negative control). The
incision was then closed with six 5–0 nylon sutures at 5-mm
intervals. Sutures were removed at seven days after wounding. The
BKS.Cg-mþ /þ Leprdb mice were killed at days 10 and 21 after
wounding for mechanical property analyses of healed wounds.
Tensile strength and tensile stiffness analyses were performed on
excised wounds. Histological evaluation was made on day 10
wounds to correlate with tensile strength/stiffness analysis. On
postoperative day 14, all NOD mice were killed, and the
mechanical properties and histology of the wounds were assessed
and compared.
With BKS.Cg-mþ /þ Leprdb mice, the mechanical properties of
linear incisional wounds were assayed 10 and 21 days after
wounding using tensiometry. NOD mice were tested on day 14
after wounding. A 30mm 8mm skin strip perpendicular to the
third incision was excised, placed in 1 PBS in an ice-water bath to
prevent desiccation, and subjected to tensiometry assays. Each skin
sample was clamped between sandpaper-covered plates with a
consistent grip-to-grip gauge length of 15mm. Samples were
centered relative to the clamps by using a custom-made alignment
apparatus. The samples were attached by the clamps to the
actuator of an Instron Servohydraulic Materials Testing System
(model 8872, Canton, MA). Tensile loads were measured
using a 2.5 lb (11.1N) load transducer (Transducer Techniques,
Temecula, CA). A preload of 0.02N was then maintained for
2minutes to define the initial length needed for engineering
strain computations. For the preloaded skin sample, the grip-to-grip
distance (that is, specimen length) was measured with
precision calipers, and the width was similarly measured along the
length of the sample. Immediately after preloading, the sample was
loaded to failure at 0.1mm/second. Two measurements were taken
from each skin sample: stiffness (N/mm), the amount of force
required to deform the skin, and breaking load (N), the amount of
force required to break (rupture) the skin sample until it no longer
possesses its integral function.
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Histology analysis on skin strips from full-thickness incisional
wounding
Skin strips from day 10 after wounding in the BKS.Cg-mþ /þ Leprdb
mice and from day 14 after wounding in the NOD mice were used
for histology analysis. The skin strips were fixed overnight in 4%
paraformaledehyde, and then the specimens were transferred into
70% ethanol for an additional 24 hours of fixation. The bisected
tissue was processed for paraffin embedding and 5-mm sections were
cut and stained with (1) H&E for evaluation of re-epithelialization
and (2) Sirius red for assessment of collagen deposition. Investigators
blinded to the treatment protocol performed the assessments. Stained
specimens were graded at the incisional site of the healed wound.
The following categories were used to grade the levels of
epithelialization: 4¼ thick and intact epithelial layer; 3¼ thick
epithelium; 2¼ complete epithelialization; 1¼minimal epitheliali-
zation; 0¼ incomplete epithelium. H&E staining was also used to
quantify the number of cells per high-powered field at  40
magnification.
Human keratinocyte cultures and scratch-wound assay
To establish keratinocyte cultures, primary human keratinocytes
were grown to 80% confluence as described earlier (Lee et al.,
2005a; Stojadinovic et al., 2006; Jho et al., 2005). At 24 hours before
the experimentation, cells were transferred to basal KBM medium
(Gibco-BRL, Grand Island, NY) (Stojadinovic et al., 2006) and
incubated in either 0.09 or 1.2mM CaCl2 to induce differentiation.
All cells were cultured from routinely discarded surgical specimens
of normal skin and cells from different wounds were not pooled in
culture. Before being wounded, cell cultures were incubated in the
presence or absence of 8mg/ml Mitomycin C (ICN, Emeryville, CA)
for 1 hour and washed with PBS to inhibit proliferation. Scratch
wounding of cell monolayers was performed as described earlier
(Lee et al., 2005a). Cultures were incubated in the presence or
absence of VEGF165 or 25 ng/ml of epidermal growth factor for 24
and 48 hours and re-photographed, and cell migration was
quantified as described earlier (Lee et al., 2005a). Thirty measure-
ments were taken for each experimental condition and the distance
coverage by cells moving into the scratch-wound area was
quantified. Three images were analyzed per condition, per time
point, and averages and standard deviations were calculated.
Human fibroblast migration assays
We grew fibroblasts from the wound base (Location A), the non-
healing edge (Location B), and the healing edge (Location C) and
compared their migration capacity with that of normal primary
dermal fibroblasts (obtained from mammoplasty). Biopsies of ischial
pressure ulcers from three different patients were used in this
experiment. The area of a pressure ulcer was prepared with Betadine
(Purdue, Stamford, CT). A sterile No. 10 blade was used to biopsy the
wound base, Location A. Then Location B was identified at the
boundary of the wound bed and the rim of necrotic or infected tissue
to be removed. After biopsy of Location B, a sharp excision was
performed to remove the entire circumferential ring of necrotic, non-
viable scar or infected tissue. Finally, a fresh blade was used to
biopsy several millimeters of adjacent non-wounded tissue, Location C.
Cells from Location B were those surgically removed and cells from
Location C were the cells left behind after surgery. Cells were grown
in DMEM (Bio Whittaker, Walkersville, MD) containing 10% calf
bovine serum and 2% antibiotic–antimycotic (Gibco, Grand Island,
NY). Twenty-four hours before the experiments, cells were switched
to basal medium—phenol red-free DMEM (Bio Whittaker) supple-
mented by 2% charcoal-pretreated bovine serum as described earlier
(Radoja et al., 2000), 1% antibiotic–antimycotic (Gibco), and 1% L-
glutamine (Cambrex Bio Science, Rockland, ME). Before the scratch,
cells were treated with 8mg/ml Mitomycin C (ICN Biomedicals,
Emeryville, CA) for 1 hour (to inhibit cell proliferation) and washed
with basal medium. Scratches were performed as described earlier
(Stojadinovic et al., 2005). Cells were incubated in the presence or
absence of 100ng/ml recombinant VEGF (R&D Systems) or 25ng
ml1 epidermal growth factor (Gibco) for 24 and 48hours and re-
photographed 24hours after the scratch.
Statistical analysis
All data were analyzed by ANOVA. The results were expressed as
mean±SD. The level of statistical significance for the comparison
between treatment with ADV/VEGF165 and treatment with saline or
just the adenovirus without VEGF165 was set at a P-value of o0.05.
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